Grover Sandeep, Chaurasia Nishtha, Chakrabarti Subho
Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Asian J Psychiatr. 2024 Dec;102:104245. doi: 10.1016/j.ajp.2024.104245. Epub 2024 Sep 13.
This retrospective study aimed to evaluate the long-term effectiveness of switching to clozapine in the management of tardive syndromes (TS).
The treatment records of patients who had TS at the time of starting clozapine, were reviewed and demographic and clinical data was extracted on a predesigned performa.
About three-fourth (74.2 %) of the study subjects had tardive dystonias and two-third (69.7 %) had tardive dyskinesia at the time of starting clozapine. About half (48.5 %) of the patients had both tardive dystonia and dyskinesia. A small proportion (13.6 %) also had tardive akathisia at the time of starting clozapine. About three-fourth (72.2 %) of the patients had >50 % reduction, and about two-third (66.6 %) of the patients had >75 % reduction and nearly half (54.5 %) of the patients had complete resolution of dyskinesia at the last follow-up. Similar trends were seen in reduction in dystonia, i.e., >50 % reduction in 74.3 %, >75 % reduction in 62.2 % and complete resolution was seen in 56.1 %.
The present study suggest that clozapine is useful in the management of drug induced tardive dyskinesia and tardive dystonia.
本回顾性研究旨在评估换用氯氮平治疗迟发性综合征（TS）的长期疗效。
回顾了开始使用氯氮平时患有TS的患者的治疗记录，并根据预先设计的表格提取了人口统计学和临床数据。
在开始使用氯氮平时，约四分之三（74.2%）的研究对象患有迟发性肌张力障碍，三分之二（69.7%）患有迟发性运动障碍。约一半（48.5%）的患者同时患有迟发性肌张力障碍和运动障碍。一小部分（13.6%）患者在开始使用氯氮平时还患有迟发性静坐不能。在最后一次随访时，约四分之三（72.2%）的患者运动障碍减轻>50%，约三分之二（66.6%）的患者运动障碍减轻>75%，近一半（54.5%）的患者运动障碍完全缓解。肌张力障碍减轻方面也有类似趋势，即74.3%的患者减轻>50%，62.2%的患者减轻>75%，56.1%的患者完全缓解。
本研究表明氯氮平在治疗药物性迟发性运动障碍和迟发性肌张力障碍方面有效。
